Tesaro — Investor Presentation (January 2013)
29 slides from Tesaro's investor presentation, Jan 7, 2013
Slide 1: January 2013 Corporate Presentation
JANUARY 2013 CORPORATE PRESENTATION
Slide 2: Company Summary
COMPANY SUMMARY Novel cancer therapeutics Differentiated oncology supportive care agents Currently advancing three pipeline products Identify and in-license or acquire Fully develop and commercialize products in-house Commercial presence in core strategic markets Management team with highly relevant
Slide 3: Product Portfolio Strategy
Assemble and advance a balanced1 portfolio of cancer therapeutics and oncology supportive care agents, including: 1Balanced by stage, resource requirements and development risk PRODUCT PORTFOLIO STRATEGY 3 Compound Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Rolapitant Oral (NK-1 receptor antago
Slide 4: Commercial Strategy
Commercialize a portfolio of cancer therapeutics and supportive care products: 1. Deploy fully integrated sales, marketing and medical affairs organizations in core strategic markets: North America: United States, Canada Europe: Germany, France, UK, Italy, Spain Asia: China 2. Establish a comprehens
Slide 5: Rolapitant Overview: Chemotherapy-Induced Nausea & Vomiting
ROLAPITANT OVERVIEW CHEMOTHERAPY-INDUCED NAUSEA & VOMITING TESARO, INC.
Slide 6: Rolapitant Overview
ROLAPITANT OVERVIEW Acquired in December 2010 from OPKO Health Schering-Plough (S-P) divested to OPKO Health as an FTC condition for its merger with Merck Potentially a Best-in-Class cancer supportive care product candidate Potent and long-acting neurokinin-1(NK-1) receptor antagonist for chemothera
Slide 7: CINV Is a Highly Debilitating Side-Effect of Chemotherapy
CINV IS A HIGHLY DEBILITATING SIDE-EFFECT OF CHEMOTHERAPY Taste Change Patient Rankings of Chemotherapy Treatment Side Effects Source: Adapted from Sun et al., Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer, Support Care Can
Slide 8: Mechanisms of CINV
MECHANISMS OF CINV Chemotherapy NK1 receptors Substance P 5-HT3 receptors Serotonin Dorsal Vagal Complex Area postrema Brainstem GI tract Enterochromaffin Cell Serotonin Release Vagal Afferent 5-HT3 Receptors Peripheral Central 8
Slide 9: Acute & Delayed CINV Driven by Different Neurotransmitters
ACUTE & DELAYED CINV DRIVEN BY DIFFERENT NEUROTRANSMITTERS Intensity of Emesis Cisplatin (HEC) Cyclophosphamide/Carboplatin (MEC) Neurotransmitter 0 1 2 3 4 5 Days Adapted from Martin M. Oncology. 1996;53 (suppl 1):26-31. Patterns of Emesis: Highly vs. Moderately Emetogenic Chemotherapy SEROTONIN NE
Slide 10: Phase 2 Design and Objectives
PHASE 2 DESIGN AND OBJECTIVES Overview Trial Design Objectives Schering-Plough evaluated the safety and efficacy of rolapitant for the prevention of CINV in 454 patients receiving HEC for up to 6 cycles of chemotherapy Multicenter, randomized, double blind, placebo controlled clinical trial Compare
Slide 11: Phase 2 Study Results
PHASE 2 STUDY RESULTS Significantly greater CR rates compared to the control group Demonstrated safety and tolerability over multiple cycles of chemotherapy A rolapitant dose of 200 mg was selected for advancement into Phase 3 clinical trials Complete Response Rate (%) *Statistically significant Not
Slide 12: Phase 2 Study Results: Nausea
PHASE 2 STUDY RESULTS Demonstrated superior treatment effect for no significant nausea versus the control group in all CINV phases Validated questionnaire (FLIE1) demonstrated statistically significant better quality of life scores for the treatment group versus the control group *Statistically sign
Slide 13: Rolapitant: A Potentially Differentiated NK-1 RA
ROLAPITANT: A POTENTIALLY DIFFERENTIATED NK-1 RA1 Product / Product Candidate Status Single Dose Oral Single Dose IV No CYP 3A4 DDI Potential Potential to Prevent Nausea2 Rolapitant Phase 3 (oral) EMEND® (aprepitant Oral & fosaprepitant IV)3 Oral 3-Day; 2003 IV 150 mg; 2010 + - - Netupitant -palonos
Slide 14: Rolapitant Highlights
ROLAPITANT HIGHLIGHTS Highly potent, long acting NK-1 receptor antagonist Differentiation includes: Long half-life Reduced risk of CYP 3A4 drug interactions Rapid onset of activity Potential for reduction in significant nausea Phase 3 on-going and results anticipated 2H:13 Significant growth potenti
Slide 15: Niraparib (PARP Inhibitor) Solid Tumors
NIRAPARIB (PARP INHIBITOR) SOLID TUMORS TESARO, INC.
Slide 16: Niraparib Overview
NIRAPARIB OVERVIEW Poly (ADP-ribose) Polymerase (PARP) Inhibitor acquired in May 2012 from Merck Potential First and Best-in-Class Orally active and potent PARP 1/2 inhibitor Compelling pharmacologic properties Unlikely to have drug-drug interactions Viable formulation Global rights and strong Intel
Slide 17: Niraparib Pre-Clinical Overview
NIRAPARIB PRE-CLINICAL OVERVIEW Potent PARP inhibition on isolated target (IC50 4nM) and in cells (20-30nM) Active in BRCA xenograft models Prolonged PARP inhibition evident in tumors following treatment with niraparib (MK-4827) MDA-MB-436 (BRCA1-mut) Tumor Volume (mm3) Residual PARP Activity in MDA
Slide 18: Phase 1 Design and Objectives
PHASE 1 DESIGN AND OBJECTIVES Overview Trial Design Objectives First in human, open-label, Phase I study Completed enrollment Oral once daily dosing; two part study Dose escalation and expansion study (n=80) evaluating 30mg – 400mg of niraparib (MK-4827) Primary Objectives: Evaluate safety and toler
Slide 19: Phase 1 Study Results
PHASE 1 STUDY RESULTS Summary of activity overall in Phase 1 (n=80) PR 12/80 (15%); 10 ovarian, 2 breast SD 24/80 (30%); ovarian, breast, 3/3 lung, other SD > 12 weeks 18/80 (22.5%) Clinical activity in ovarian patients (n=39 evaluable) PR 10/39 (26%); SD 13/39 (33%) BRCA+ patients: PR 7/19 (37%); S
Slide 20: Niraparib Development Plan
NIRAPARIB DEVELOPMENT PLAN Design optimal development plan based upon: Phase 1 trial results Collective experience review of PARP inhibitor clinical studies Discussions with experienced clinical investigators and scientists Biomarker/patient selection strategy Potential cancer targets include breast
Slide 21: TSR-011 (ALK Inhibitor) NSCLC and Other Cancers
TSR-011 (ALK INHIBITOR) NSCLC AND OTHER CANCERS TESARO, INC.
Slide 22: TSR-011 Overview
TSR-011 OVERVIEW Global rights to AMGEN’s Anaplastic Lymphoma Kinase (ALK) Program acquired in March 2011 A potentially Best-in-Class molecularly targeted approach to treating certain cancer sub-populations TSR-011 is a highly selective and potent oral compound that possess desirable pharmaceutical
Slide 23: ALK Inhibition Blocks Key Pathways for Cancer Cell Survival
ALK INHIBITION BLOCKS KEY PATHWAYS FOR CANCER CELL SURVIVAL ALK-fusion first identified in lymphoma ALK activating mutations are present in NB and nearly 100% of NB overexpress ALK ALK-fusions (multiple partners) in NSCLC and CRC ALK amplification recently identified in inflammatory breast Cancer AL
Slide 24: TSR-011 Pre-Clinical Overview
TSR-011 PRE-CLINICAL OVERVIEW Excellent pharmaceutical properties Orally bioavailable, large volume of distribution, low clearance and long half-life predicted in humans Highly selective and significantly more potent than crizotinib; potentially: Less frequent dosing (more potent, longer acting) Sus
Slide 25: TESARO ALK Inhibitors Show Excellent In Vivo Inhibition and Tumor Regression
TESARO ALK INHIBITORS SHOW EXCELLENT IN VIVO INHIBITION OF ALK AND TUMOR REGRESSION Sustained ALK inhibition in vivo Slow off-rate may ensure prolonged ALK inhibition and tumor regression TESARO ALK inhibitors cause tumor regression in Karpas-299 tumors (ALCL) ALK inhibition in tumors is maintained
Slide 26: TSR-011 Development Plan
TSR-011 DEVELOPMENT PLAN Plan to develop TSR-011 patients with NSCLC whose tumors have altered ALK proteins Phase 1/2 study ongoing; study objectives: Determine the maximum tolerated dose of TSR-011 Define an optimal dosing schedule Assess safety and anti-tumor activity Data will provide an assessme
Slide 27: Summary
SUMMARY TESARO, INC.
Slide 28: Summary
SUMMARY Late stage oncology supportive care product Differentiated product profile Phase 3 data expected 2H:13 Significant market potential Rapidly advancing a development-stage pipeline of cancer therapeutics Potentially First and Best-in-Class PARP inhibitor Potentially Best-in-Class ALK inhibitor
Slide 29: Mission Statement
An oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and commercializing safer and more effective supportive care agents and therapeutics. MISSION STATEMENT 30